As Natco Ups The Ante Lilly Readies Voluntary Licensing For Olumiant

Eli Lilly responds with baricitinib donation plan and efforts to sew up royalty free voluntary licenses with local Indian firms as challenger Natco seeks a compulsory license for its version of the JAK inhibitor, which it is ready to launch.

Natco Spurs Licensing Action For Baricitinib? • Source: Alamy

Whether spurred by the actions of local challenger Natco Pharma Limited or not, Eli Lilly and Company is now pursuing voluntary licensing in India for its rheumatoid arthritis drug baricitinib (available internationally as Olumiant) used in combination with remdesivir as a COVID-19 therapy.

Lilly’s seemingly changed approach is significant – indeed has been termed "reactionary" by some industry experts – given that local...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip